AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04487041 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose influenza vaccination
Description: 4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle
Study NCT02854072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
Study NCT02854072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
Study NCT02854072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
Study NCT02854072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.
Study NCT02854072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.
Study NCT03628092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 Fractional Ablative Laser
Description: Vaginal / vulval laser treatment
Study NCT03628092 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham Device
Study NCT02182895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 2.5-5 mg daily
Study NCT03938311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early rehabilitation
Description: The three study groups share a same intervention protocol in addition to the initiation timing of intervention from the stroke onset. The frequency and intensity of the intervention is titrated according to functional activity baseline and monitored daily and adjusted with recovery. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed.
Study NCT02492035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Study NCT03002441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Same-Day Dilapan-S
Description: Dilapan-S cervical dilators placed the same day as the D\&E procedure
Study NCT03002441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overnight Dilapan-S
Description: Dilapan-S cervical dilators placed the day prior to D\&E procedure
Study NCT04310540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04310540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04310540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV
Study NCT04310540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04310540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT01088789 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
Description: A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.~The vaccine is administered every 6 months.
Study NCT04044690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human immunoglobulin G
Description: human immunoglobulin G administered subcutaneously
Study NCT04044690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously
Study NCT00667628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC-101
Description: Participants received TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
Study NCT00667628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo (two matching tablets) at same frequency and duration of active treatment.
Study NCT02548546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECHO
Description: Imaging
Study NCT02548546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECG-gated MRA
Description: Imaging
Study NCT04601818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Preserving of Donor Lungs
Description: lung transplants that have a proposed after hours start time will be delayed until 6am and the donor lungs will be preserved for no more than 12 hours at 10 degrees celsius cold static
Study NCT04212416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO
Study NCT03486821 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation
Description: All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.
Study NCT01105819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus plantarum 299 for oral care
Description: The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
Study NCT01105819 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chlorhexidine for standard oral care
Description: A The control group will receive the standard oral care of the department (general ICU, Lund University Hospital).~This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
Study NCT00271635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 capsules b.i.d. during 1 year
Study NCT00271635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
Study NCT06420804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZIIP Acne Treatment Device
Description: Evaluation of the Safety and Efficacy of a ZIIP Acne Treatment Device
Study NCT03388346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA-HBED-CC PET
Description: Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
Study NCT01626326 — intervention group
Intervention type: BEHAVIORAL
Intervention: San Francisco Stop Smoking iPhone app
Description: iPhone app designed to help people quit smoking
Study NCT02049775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NBI
Study NCT01657383 — intervention group
Intervention type: PROCEDURE
Intervention: HPB Surgery
Description: Hepatopancreatico Biliary Surgery
Study NCT02931188 — intervention group
Intervention type: DRUG
Intervention: Anacetrapib
Description: No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Study NCT02931188 — intervention group
Intervention type: DRUG
Intervention: Statin
Description: No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Study NCT02931188 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Study NCT02262936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Study NCT02262936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fesoterodine
Study NCT03826706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC Videolaryngoscope D blade
Description: C-MAC videolaryngoscope D blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
Study NCT03826706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC Videolaryngoscope X3 blade
Description: McGrath MAC videolaryngoscope X blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
Study NCT01225874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-PEG E. coli L-asparaginase
Description: Given IM
Study NCT01493843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
Study NCT04678999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body exercise and education
Description: The intervention will delivered via a secure Zoom video platform.
Study NCT01404195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Plus Advance
Description: Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week
Study NCT01225874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT
Study NCT01225874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT01225874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT01225874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT
Study NCT01225874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM
Study NCT01225874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT01225874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT01537666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AeroVanc
Description: Vancomycin hydrochloride dry powder for inhalation
Study NCT01537666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV vancomycin hydrochloride
Description: Vancomycin hydrochloride solution for intravenous administration
Study NCT00754663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: walking training at least 3 times a week
Study NCT00754663 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise training
Description: walking training at least 3 times a week
Study NCT03041038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Anti IL-17A antibody
Study NCT03041038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01721135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg
Description: Film coated oral tablet
Study NCT01721135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 200mg
Description: Film coated oral tablet
Study NCT00386373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
Study NCT02903264 — intervention group
Intervention type: OTHER
Intervention: Gestational diabetes mellitus
Study NCT01721135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 400mg
Description: Film coated oral tablet
Study NCT01721135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin placebo
Description: Film coated oral tablet
Study NCT01721135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin placebo
Description: Film coated oral tablet
Study NCT01721135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 placebo
Description: Film coated oral tablet
Study NCT01721135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2190915 placebo
Description: Film coated oral tablet
Study NCT01721135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK2190915 placebo
Description: Film coated oral tablet
Study NCT00005906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.
Study NCT00481832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 4 gm /m² IV over 2 hours on day 8
Study NCT00481832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)
Study NCT00481832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².
Study NCT00481832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis
Study NCT00481832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: 1.5 mg/kg/d, IV from day -11 to -7
Study NCT00481832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 5mg/kgbid,variable, po or IV
Study NCT00481832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.
Study NCT00481832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..
Study NCT00481832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (auto-HSCT)
Description: Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
Study NCT00481832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Description: Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
Study NCT00481832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation
Description: TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
Study NCT00481832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD34+ Cells
Description: 2 x 10e6 CD34+ cells per kg actual body weight on Day 0
Study NCT00481832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Medrol
Description: 1 mg/kg, Day-11 to Day-7
Study NCT02558894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 monotherapy
Description: MEDI4736 via IV infusion.
Study NCT02558894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab+MEDI4736
Description: tremelimumab+MEDI4736 via IV infusion.
Study NCT01415271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Communication
Description: bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist
Study NCT01258543 — intervention group
Intervention type: OTHER
Intervention: General Osteopathic Evaluation
Description: 2 general osteopathic evaluations of approximately 1 hour in duration done consecutively on the same day with a 15 minute break between evaluations
Study NCT01615250 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramyocardial implantation of stem cells
Description: Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.
Study NCT02928068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching (OPC)
Description: OPC focuses on increasing positive child-caregiver interactions and child learning opportunities in everyday routines and contexts, which positions families for improved trajectories over time. OPC capitalizes on families' strengths, while supporting caregivers in using their own resources and ideas to advance child function. Caregivers identify goals, while therapists ask reflective questions and make reflective comments, affording caregivers an opportunity to gain a deeper understanding of their own current knowledge and the impact of their strategies on their children's adaptive behavior. Thus, families generate their own solutions and are ultimately responsible for carrying out the intervention and evaluating its effectiveness.
Study NCT04151940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT04151940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study NCT04151940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive standard of care chemotherapy
Study NCT04151940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive standard of care immunotherapy
Study NCT04151940 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy
Study NCT04201431 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PvDBPII/Matrix-M1
Description: 50ug PvDBPII in 50ug Matrix M1
Study NCT04586478 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single dose of CNCT19
Description: Dose: 2.00 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
Study NCT03864835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise
Description: Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist. This is feasible as Zhang et al.(87) found 66 out of 70 subjects (95%) completed the twelve-month supervised in-person moderate-intensity exercise protocol five-days a week.
Study NCT00375999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and epirubicin
Study NCT01754103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile Training
Description: Tactile Training to induce neuroplasticity in the visual pathway, measured with functional connectivity MRI